PP
STRO icon

PDT Partners’s Sutro Biopharma STRO Stock Holding History

PDT Partners’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,466
Closed -$414K – 883
2022
Q3 		$414K Sell
7,466
-3,726
-33% -$221K 0.06% 489
2022
Q2 		$583K Buy
11,192
+3,105
+38% +$173K 0.05% 561
2022
Q1 		$665K Buy
+8,087
New +$770K 0.06% 498

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

PDT Partners's STRO Position: Q4 2022 in Review

PDT Partners sold out of Sutro Biopharma (STRO) in Q4 2022, closing a stake of 7,466 shares — an estimated $414K sold.

PDT Partners first reported a position in STRO in Q1 2022 and held it in 3 quarters. The position peaked at $665K in Q1 2022. 118 funds tracked by Wall St. Rank hold STRO as of Q4 2022.

  • PDT Partners reported no remaining Sutro Biopharma position as of Q4 2022 after selling out during the quarter.
  • PDT Partners sold 7,466 Sutro Biopharma shares in Q4 2022, an estimated $414K.
  • PDT Partners first reported a position in Sutro Biopharma in Q1 2022 and held it in 3 quarters.
  • PDT Partners's Sutro Biopharma position peaked at $665K in Q1 2022.
  • 118 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.